Q/C Technologies (QCLS) investor relations material

Executive summary

• Shifted strategic focus to proprietary silicon photonic computing for AI inference, discontinuing the LightSolver license and blockchain initiatives.

• Headquarters relocated to San Francisco to support the optical processing unit (OPU) initiative and integrated photonics lab.

• Legacy pharmaceutical assets (Isomyosamine, Supera-CBD) retained, with strategic alternatives under evaluation.

Financial highlights

• Net loss of $6.62 million for Q2 2026, compared to $1.80 million in Q2 2025; net loss of $7.86 million for the six months ended June 30, 2026, versus $2.92 million in the prior year period.

• No revenue generated from product sales; only investment income recognized.

• Operating expenses for Q2 2026: $1.00 million in G&A, $236k in R&D, $2.37 million in stock-based compensation, and $3.18 million impairment of technology license.

• Cash and cash equivalents of $0.3 million and marketable securities of $10.68 million as of June 30, 2026.

• Working capital of $8.18 million and stockholders' equity of $16.09 million at quarter end.

Outlook and guidance

• Management believes current financial resources are sufficient to fund operations and contractual obligations for at least the next twelve months.

• Substantial additional funding will be needed to support ongoing development and commercialization of photonic computing products.

• No meaningful revenue expected until successful development and commercialization of new products.